| # | Country | Total Patents | |
|---|---|---|---|
| #1 | United States | 3 | |
| #2 | EPO (European Patent Office) | 2 | |
| #3 | Canada | 1 | |
| #4 | Hungary | 1 | |
| #5 | Republic of Korea | 1 | |
| #6 | Serbia | 1 | |
| #7 | Russian Federation | 1 | |
| #8 | WIPO (World Intellectual Property Organization) | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Organic fine chemistry |
| # | Technology | |
|---|---|---|
| #1 | Therapeutic chemical compounds | |
| #2 | Heterocyclic compounds | |
| #3 | Medical preparations | |
| #4 | Organic chemistry methods |
| # | Name | Total Patents |
|---|---|---|
| #1 | Chen Xiangyang | 11 |
| #2 | Gao Yingxiang | 6 |
| #3 | Liu Chong | 6 |
| #4 | Mulvihill Mark | 6 |
| #5 | Ni Haihong | 6 |
| #6 | Zhou Chao | 4 |
| #7 | Kong Norman Xianglong | 4 |
| #8 | Pang Yucheng | 1 |
| Publication | Filing date | Title |
|---|---|---|
| WO2020259584A1 | Heterocyclic compounds for mediating tyrosine kinase 2 activity | |
| KR20190035870A | As the FGFR inhibitor, the heterocyclic compound | |
| RU2677884C2 | Substituted nicotinimide inhibitors of btk, their preparation and use in treatment of cancer, inflammation and autoimmune diseases | |
| HUE050771T2 | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease |